External reports (aggregated public sources), Value Investors Club

Value Investors Club

External reports (aggregated public sources)

Equity Bottom-Up

<ul><li>Abeona is developing a cell therapy for the rare disease RDEB, with FDA review ongoing and a target action date of May 25th</li><li>The therapy is expected to have a significant impact on RDEB patients, who face severe skin and GI issues due to a lack of specific collagen</li><li>With a niche business model focused on treating a small patient population, Abeona anticipates generating over $100 million in free cash flow and potentially offering significant upside for investors.</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

Abeona is developing a cell therapy for the rare disease RDEB, with FDA review ongoing and a target action date of May 25thThe therapy is expected to have a significant impact on RDEB patients, who face severe skin and GI issues due to a lack of specific collagenWith a niche business model focused on treating a small patient population, Abeona anticipates generating over $100 million in free cash flow and potentially offering significant upside for investors.This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Abeona Therapeutics Inc (ABEO) - Thursday, Feb 15, 2024

United States

Seres Therapeutics, Inc. operates as a microbiome therapeutics platform company. The Company focuses on developing biological drugs, which are designed to restore health by repairing the function of a dysbiotic microbiome. Seres Therapeutics also conducts research on metabolic diseases.

XBiotech Inc. is a clinical-stage biopharmaceutical company. The Company discovers and develops monoclonal antibodies for treating a variety of diseases, such as cancer, vascular disease, inflammatory skin disease, and diabetes.

Merrimack Pharmaceuticals, Inc. operates as a biotechnology company. The Company focuses on the discovery and development of drugs for the treatment of immunological and autoimmune diseases. Merrimack Pharmaceuticals serves patients in the United States.

Agenus, Inc. develops vaccines.  The Company researches vaccines for brain cancer, kidney cancer, herpes, lung cancer, melanoma, malaria, shingles, and Alzheimer's disease.

Lineage Cell Therapeutics, Inc. operates as a biotechnology company. The Company offers cell-based therapies and gene marker-based molecular diagnostics for diseases and degenerative conditions. Lineage Cell Therapeutics serves patients in the United States.

Coherus Biosciences Inc., is a biopharmaceutical company. The Company develops biosimilar therapeutics to aid patients.

Inovio Pharmaceuticals, Inc. researches and develops pharmaceuticals.  The Company develops cancer DNA and infectious DNA vaccines, anti-inflammatory drugs, and animal health products.

Spectrum Pharmaceuticals Inc. is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology. The Company's strategy is comprised of acquiring, developing and commercializing a broad and diverse pipeline of late-stage clinical and commercial products.

Bluebird Bio, Inc. provides biotechnological products and services. The Company offers gene therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders, and beta-thalassemia. Bluebird Bio conducts its business in the United States.

Actinium Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. The Company develops pipeline of antibody radiation conjugates for targeted conditioning and combination therapies. Actinium Pharmaceuticals serves clients in the United States.

Genexine Co., Ltd. is bio technology company. The Company specialize in the development of therapeutic vaccines and next generation antibody fusion protein medications.

Japan Tissue Engineering Company., Ltd. is a medical biotechnology company. The Company develops regenerative medicine using tissue engineering technology. Japan Tissue Engineering also provides research support services.

Dimerix Limited operates as a biotechnology company. The Company focuses on developing and marketing drug therapies, as well as provides clinical trials for treating patients with chronic kidney diseases. Dimerix serves patients in Australia.

Pharma Foods International Co.,Ltd. produces and sells bioengineered foods for commercial use.  The Company researches and develops physiologically functional foods.

Pharmicell Co.,Ltd. is a Biotechnology company.  The Company's business area inlcudes stem cell therapeutics, Stem cell banking, Bio-based business and Cosmetics.

Xinjiang Tianshan Animal Husbandry Bio-engineering Co Ltd develops cattle breed and genetic improvements. The Company's main products include high quality cattle semen, embryos as well as other genetic material and related services.

Xinjiang Tianshan Animal Husba (300313 CH)

Amicogen, Inc. develops, produces and markets specialty enzymes and functional food ingredients. The Company offers special biocatalysts,  enzyme-based new functional materials, health foods, and consumer products.

Innate Pharma S.A. is a biopharmaceutical company.  The Company develops first in class drugs that focus on cancer immunotherapy through the manipulation of the innate immune system.

Molecular Partners AG develops and markets biopharmaceutical products. The Company develops designed ankyrin repeat protein platform therapies used in ophthalmology, oncology, inflammation, and other therapeutic treatments. Molecular Partners serves healthcare professionals and patients internationally.

Race Oncology Limited operates as a specialty pharmaceutical company. The Company focuses on rediscovering and bringing to market the cancer chemotherapy agent, Bisantrene.

Abeona Therapeutics Inc. is a leading clinical-stage biopharmaceutical company. The Company develops novel gene therapies for life-threatening rare diseases.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00